Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › VIYASH

VIYASH

Viyash Scientific Limited
Micro-capPharma ↗

What the six lenses say about VIYASH — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹263.6
2026-09-08
VWAP · 1Y anchor
₹248
+6.3% from VWAP
P/E · TTM
54.7×
TTM EPS ₹4.8
52-week range
76%
position low→high
RSI(14)
49
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How VIYASH’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD895›

The actual numbers

Price vs VWAP (1y)+6.3%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+12.8%
Price vs 50-EMA+0.6%
RSI(14)49
RS vs Nifty 500 · 3M+0.3%
RS vs sector · 3M-5.8%
52-week range76%
Volume vs 30d avg0.31×
Volume vs 60d avg0.50×
ATR(14) · volatility10.6
Bollinger width · vol contraction0.107
FundamentalD857›

The actual numbers

Return on equity (ROE)7.1%
Operating margin12.7%
Net margin6.7%
Revenue growth · YoY+97.8%
EPS growth · YoY+454.0%
Debt / equity0.17×

Full 8-quarter history in the financials table below.

ValuationD29›

The actual numbers

P/E (TTM)54.7×
TTM EPS₹4.8
52-week range76%
CatalystD849›

The actual numbers

Earnings & momentum56
Capital actions12
Governance100

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding61.3%
Delivery · 30d avg53.2%
Up/down-day asymmetry0.5pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D4 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
91
Conviction score 91/100 · avg-decile strength 6.0/10
Conviction score91/100›
TechnicalD8›
FundamentalD8›
ValuationD2›
CatalystD8›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.3pp
+1.3pp
+0.2pp
+1.9pp
+32.7pp
+46.0pp
Nifty 500
Broad-market baseline
-0.4pp
+1.3pp
-0.9pp
+0.3pp
+27.0pp
+40.8pp
Sector
Own-sector index
—
—
-3.7pp
-5.8pp
+13.8pp
+20.0pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

VIYASH daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
263.65-2.20

Relative strength

RS vs baseline · rebased to 100

VIYASH ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
152.03-0.62

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)390369391402441850858920
↳ change QoQ—-5.5%+6.0%+2.9%+9.7%+92.7%+0.9%+7.2%
EBITDA (₹cr)4539404652173176184
EBITDA margin11.4%10.7%10.2%11.4%11.8%20.3%20.5%20.0%
PAT (₹cr)9661018734966
↳ change QoQ—-30.0%+2.2%+54.3%+80.0%+305.6%-32.9%+34.7%
Net margin2.3%1.7%1.7%2.5%4.1%8.6%5.7%7.2%
EPS (₹)0.260.100.140.370.572.180.881.19
D/E————————
YoY growth · Mar '26Revenue +128.9% YoYPAT +560.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Jul '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds VIYASH

Mutual funds holding VIYASH (4)

FundWeightAUM ₹crGrade
Quant Small Cap Gr0.83%34,069
UTI Healthcare Reg Gr1.98%1,371
Bandhan Healthcare Reg Gr0.77%319
Samco Multi Cap Reg Gr0.51%228

ETFs holding VIYASH (0)

No tracked ETF holds VIYASH ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma